Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102497 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL103308 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL199750 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL102914 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL101878 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL7888892 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL7939027 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL101629 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL103793 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL199645 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478605-B | Trinuclear borate and preparation method thereof, catalyst system and olefin polymerization method | 万华化学集团股份有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-111689995-B | High-solubility triaryl carbon borate and preparation method and application thereof | 万华化学集团股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-115477634-A | Compound for analgesia and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-12-16 | — | — | CN | claimed |
| CN-114478605-A | Highly soluble and highly steric-hindrance trinuclear borate, preparation method thereof, catalyst system and olefin polymerization method | 万华化学集团股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-111689995-A | High-solubility triaryl carbon borate and preparation method and application thereof | 万华化学集团股份有限公司 | 2020-09-22 | — | — | CN | claimed |
| CN-110003997-A | A kind of textile garment degreasing dry cleaning agent and preparation method thereof | 广州市保洁星科技发展有限公司 | 2019-07-12 | — | — | CN | claimed |
| US-8410161-B2 | Thioxanthone ring system derivatives | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-04-02 | — | — | US | claimed |
| US-20120088810-A1 | THIOXANTHONE RING SYSTEM DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-04-12 | — | — | US | claimed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | claimed |
| WO-2024147345-A1 | COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES | ＡＰＢ株式会社 | 2024-07-11 | — | — | WO | disclosed |
| CN-115232184-B | Ribofuranosylpyridine derivatives, pharmaceutical compositions and uses thereof | 宁波熙健医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113039659-B | Self-assembled monolayers for electrode modification and devices comprising such self-assembled monolayers | 默克专利有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20240191009-A1 | POLYFUNCTIONALIZED HIGH-CIS 1,4-POLYBUTADIENE AND METHOD FOR MANUFACTURING THE SAME | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2024-06-13 | — | — | US | disclosed |
| EP-0188384-A1 | Phosphate ester derivatives, and their use as anti-cancer agents | SANKYO COMPANY LIMITED (JP) | 1986-07-23 | — | — | EP | disclosed |
| EP-0138558-A2 | Phospholipids and their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-04-24 | — | — | EP | disclosed |
| US-4280966-A | CHLORINATION OF ALKANETHIOLS OR DIALKYL DISULFIDES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-07-28 | — | — | US | disclosed |
| US-4254214-A | BLACK, REDUCTION OF COPPER SALT OR COMPLEX TO COPPER | FUJI PHOTO FILM CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
| US-4188403-A | Cyclopentan-1-amines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-02-12 | — | — | US | disclosed |
| US-4000275-A | BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES | ELI LILLY AND COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088810-A1 | THIOXANTHONE RING SYSTEM DERIVATIVES | TST, TXN, XDH | ACE2 2405/4885OPRM1 930/4885SPHK1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.